Currently, out of the existing stock ratings of Keay Nakae - 98 which are a Buy (78.4%), 19 which are a Hold (15.2%), 8 which are a Sell (6.4%)

Keay Nakae

Work Performance Price Targets & Ratings Chart

Analyst Keay Nakae works at CHARDAN CAPITAL and is covering the Healthcare sector with 208 price targets and ratings displayed on 30 stocks.

Keay Nakae's average stock forecast success ratio is 38.21% with an average time for price targets to be met of 63.29 days.

Most recent stock forecast was given on PRQR, ProQR Therapeutics N.V at 08-Nov-2023.

Wall Street Analyst Keay Nakae

Analyst best performing recommendations are on OCGN (OCUGEN).
The best stock recommendation documented was for OCGN (OCUGEN) at 2/8/2021. The price target of $13 was fulfilled within 1 day with a profit of $2.81 (17.77%) receiving and performance score of 177.74.

Average potential price target upside

of $52.9 (40.72%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $33.34 (52.01%) on SONN.
of $25.13 (72.62%) on AXLA (AXCELLA HEALTH).

ABUS Arbutus Biopharma ARWR Arrowhead Pharmaceuticals AXLA Axcella Health DRNA Dicerna Pharmaceuticals EBS Emergent BioSolutions KLDO Kaleido BioSciences MESO Mesoblast OCGN Ocugen PEAR SONN EVLO Evelo Biosciences FBRX LJPC La Jolla Pharmaceutical Company PHGE PRQR ProQR Therapeutics N.V CFRX FEMY NBSE RNA SABS MCRB Seres Therapeutics SYBX Synlogic ALNY Alnylam Pharmaceuticals BTTX DYN GANX KMDA OCX OncoCyte SLN XCUR

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ed Arce (HC WAINWRIGHT)